Lite Strategy, Inc. filings document the company’s public-company transition, operating results, Litecoin treasury strategy, and capital-allocation actions. Form 8-K disclosures include furnished financial results, the board-authorized common stock repurchase program, and equity securities activity tied to pre-funded warrants issued in a private placement.
The filings also cover governance and compensation matters, including annual meeting voting results, director elections and resignation, executive appointment to chief executive officer and the board, stock option grants, and approval of the 2026 Omnibus Equity Compensation Plan. SEC reports identify MEI Pharma, Inc. as the company’s former name and support the current Lite Strategy identity.
Lite Strategy, Inc. reported fiscal 2026 third quarter results, emphasizing its strategy of using Litecoin (LTC) as its primary treasury reserve asset and returning capital to shareholders. The company highlighted its active covered call options program, which has generated $0.7 million in net proceeds since October 2025.
Lite Strategy deployed covered call proceeds and 35,250 LTC to repurchase 1,629,136 shares under a broader $25 million share repurchase authorization, reflecting a focus on capital discipline and net asset value per share. Management also noted ongoing pre-clinical pharmaceutical programs as potential sources of non-dilutive capital.
The company framed recent Securities and Exchange Commission guidance indicating Litecoin exhibits digital commodity characteristics as a meaningful step toward regulatory clarity. Looking ahead, Lite Strategy plans to scale its options program, continue repurchases, and pursue strategic investments and partnerships that support broader Litecoin ecosystem growth.
Lite Strategy, Inc. reported a sharp increase in losses as it pivoted from drug development toward a Litecoin-focused treasury strategy for the quarter ended March 31, 2026. The company recorded a net loss of $23.7 million for the quarter and $58.1 million for the nine months, largely driven by a $46.0 million nine‑month loss from changes in the fair value of digital assets and related receivables.
Total assets rose to $57.8 million, dominated by $48.2 million of Litecoin-related digital assets and receivables, while cash and cash equivalents declined to $7.5 million. A $100.0 million PIPE financing in July 2025 funded the acquisition of LTC and new advisory and asset management warrants.
The company also authorized a $25.0 million share repurchase program and bought back about 1.6 million shares for $2.0 million during the nine months. Lite Strategy began writing covered call options on its LTC holdings to generate cash, exposing results to further digital asset price volatility under new fair value accounting.
Citadel-affiliated entities and Kenneth Griffin report beneficial ownership of Lite Strategy, Inc. common stock on an amended Schedule 13G. Griffin may be deemed to beneficially own 1,433,211 Shares, representing 3.9% of the outstanding common stock.
Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may each be deemed to beneficially own 1,085,626 Shares, or 3.0% of the class. Citadel Securities LLC, Citadel Securities Group LP and Citadel Securities GP LLC may each be deemed to beneficially own 347,585 Shares, or 0.9% of the class.
The ownership percentages are based on 36,769,677 Shares outstanding as of December 15, 2025. The reporting group certifies the securities were not acquired and are not held for the purpose of changing or influencing control of Lite Strategy.
Lite Strategy, Inc. reported fiscal 2026 second quarter results centered on a new, more active use of its Litecoin treasury and capital return strategy. The company began transforming its LTC holdings into a “productive reserve asset” by launching a covered call options program that generated nearly $600,000 in gross premiums in the quarter.
Management also used proceeds from these treasury operations to commence a $25 million stock repurchase program, aiming to practice disciplined capital allocation and address the discount to net asset value. As of December 31, 2025, Lite Strategy held $8.8 million in cash and cash equivalents and initiated pre-clinical R&D work on its drug candidate pipeline for potential out-licensing or sale opportunities.
Lite Strategy, Inc. reported a sharp increase in scale and a major shift in strategy for the quarter ended December 31, 2025. Total assets rose to $82.9 million from $18.3 million in June, driven mainly by $63.97 million of Litecoin holdings and $7.35 million of digital assets receivable tied to covered call option activity.
The company recorded a quarterly net loss of $30.8 million, compared with $2.7 million a year earlier, largely due to a $26.5 million decrease in the fair value of digital assets and related receivable remeasurement. Lite Strategy closed a $100.0 million PIPE in July 2025, issued common stock and pre-funded warrants, and then deployed $100.0 million to purchase Litecoin, adopting a Litecoin Treasury Strategy alongside its legacy oncology pipeline. It also authorized a $25.0 million share repurchase program and began buying back stock, repurchasing 137,541 shares for $0.2 million during the quarter, while ending with $8.8 million in cash and cash equivalents.
Lite Strategy, Inc. reported that CEO, CFO and Secretary Justin J. File acquired a stock option covering 455,000 shares of common stock at an exercise price of $2.02 per share on February 12, 2026, as employment compensation.
The option grant was approved by the board on November 20, 2025, subject to shareholder approval of the 2026 Stock Omnibus Equity Compensation Plan, which shareholders approved on February 12, 2026. After this grant, File directly holds 635,000 derivative securities.
The option is 5.6% vested and exercisable as of February 12, 2026, with the remaining 94.4% vesting in 34 monthly installments beginning February 14, 2026, contingent on continued service.
Lite Strategy, Inc. reported results of its fiscal 2026 Annual Meeting held on February 12, 2026. Stockholders approved the 2026 Omnibus Equity Compensation Plan, which became effective upon approval and supports the company’s future stock-based incentive awards.
Approval of the 2026 plan also satisfied the contingency for previously disclosed Replacement Options granted to Mr. Justin J. File to purchase 455,000 shares of common stock. Stockholders elected Mr. File and Mr. Joshua Riezman as directors to terms running through fiscal 2029, approved an advisory vote on executive compensation, and ratified CBIZ CPAs as independent auditors for the fiscal year ending June 30, 2026.
At the meeting, 19,437,130 shares of common stock were represented by proxy out of 36,785,397 shares outstanding and entitled to vote, indicating substantial shareholder participation.
Lite Strategy, Inc. (LITS) reported an amended insider transaction showing the grant of 180,000 stock options to its CEO, CFO and Secretary, who also serves as a director. The options have an exercise price of $2.02 per share and were granted on 11/14/2025.
These options were received as employment compensation and vest in 36 monthly installments, with the first installment vesting one month after the grant date, subject to continued service. The amendment states that a prior filing on 11/18/2025 inadvertently reported the number of options granted, and this filing corrects that amount to 180,000 options.
Lite Strategy, Inc. filed an amended report to correct the previously disclosed size of stock options granted to its Chief Executive Officer, Justin J. File. The original filing stated that Mr. File received options to purchase 635,000 shares of common stock, but the actual grant on November 14, 2025 was for options on 180,000 shares under the company’s existing equity plan.
To address this discrepancy, on November 20, 2025 the board approved additional “Replacement Options” for Mr. File to purchase 455,000 shares of common stock. These replacement options carry an exercise price of $2.02 per share and follow the same vesting terms as the original 180,000-share grant. The replacement options will only be issued if stockholders approve a new omnibus equity plan at the company’s 2026 annual meeting; they will be cancelled if that plan is not approved.